Literature DB >> 1424820

Epidemiology of pain requiring strong analgesics outside hospital in a geographically defined population in Denmark.

H T Sørensen1, H H Rasmussen, J F Møller-Petersen, E Ejlersen, H Hamburger, F Olesen.   

Abstract

Based on obligatory notifications from pharmacies to the National Board of Health about prescription of strong analgesics as well as questionnaires to the prescribing doctors, the occurrence and causes of pain requiring strong analgesics outside hospitals were analysed over a period of one month in Denmark in a limited population (480,000), corresponding to nearly 10% of the Danish population. During one month, strong analgesics were prescribed to 0.2 per cent of the population. The commonest acute conditions were back pain (23%) and trauma (17%). The commonest recurrent acute conditions were headache (25%) and angina pectoris (17%). The commonest chronic non-malignant conditions were back pain (29%) and pancreatitis (7%). The commonest malignant conditions were lung cancer (20%) and colorectal cancer (14%). The commonest conditions indicated under the chronic pain syndrome were headache (33%) and back pain (13%). Conditions requiring strong analgesics reflect to some extent the distribution of painful conditions in the general population.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1424820

Source DB:  PubMed          Journal:  Dan Med Bull        ISSN: 0907-8916


  3 in total

Review 1.  Medical Management of Pain in Chronic Pancreatitis.

Authors:  Vikesh K Singh; Asbjørn M Drewes
Journal:  Dig Dis Sci       Date:  2017-05-18       Impact factor: 3.199

2.  Opioid treatment of painful chronic pancreatitis.

Authors:  T Niemann; L G Madsen; S Larsen; N Thorsgaard
Journal:  Int J Pancreatol       Date:  2000-06

3.  Identification of patients treated with strong analgesics: an assessment of two Danish information systems with respect to epidemiological research.

Authors:  H T Sørensen; I Hansen; E Ejlersen; S Sabroe; H Hamburger
Journal:  J Med Syst       Date:  1996-02       Impact factor: 4.460

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.